ARCHIVES

Economic Analyses Of New Therapies Useful In Phase III Studies, Trialists Say

This article is from The Cancer Letter archive.

Vol. 35 No. 29 | July 24, 2009

Download PDF Visit The Full Archive

Related Articles

NCI Funds Proteomic Technology Assessment Grants.

September 29, 2006

NCI Raises R01 Payline To 16th Percentile FY09. Coalition Formed To Advocate For Medical Innovation

March 27, 2009

Army Will Outspend NCI In Breast Cancer In FY93, But How To Apply For a Grant?

October 16, 1992

DeVita Considers Laetrile Tests

June 3, 1977

ASCO Awards Contract For D.C Office

January 12, 1990

PV-10 Produces 51 Percent Response Rate in Phase II Trial

October 26, 2012